Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy

Noot, Martin R. Vander; Eloubeidi, Mohamad; Chen, Victor K.; Eltoum, M.B.A. Isam A.; Jhala, Darshana; Jhala, Nirag; Syed, Sujath; Chhieng, M.B.A. David C.

doi:10.1002/cncr.20360

Cited by 219 publications

(134 citation statements)

References 61 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…23,24 Several studies have looked at the diagnostic yield of EUS with FNA for the diagnosis of GIST. [25][26][27] The sensitivity and diagnostic yield of this technique ranges between 75% and 85%. EUS can also help to identify extramural lesions and differentiate vascular vs. solid lesions.…”

Section: Clinical Presentation and Diagnosismentioning

confidence: 99%

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Iorio

Sawaya

Friedenberg

2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY BackgroundGastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract with an increasing incidence. AimsTo review the biology, diagnosis and treatment of gastrointestinal stromal tumours. MethodsA PubMed search using the phrases 'Gastrointestinal stromal tumor', 'imatinib', 'c-kit'. ResultsThe diagnosis of GIST is established by histology supplemented by the immunohistochemical marker CD117, which is positive in 95% of cases. The most common site of the tumour is the stomach. Most GIST are benign with 20-30% malignant. Five-year survival for malignant GIST ranges between 35% and 65% and depends primarily on tumour size, mitotic index and location. The malignant behaviour of GIST is best assessed by invasion of adjacent structures and distant metastases. The gold standard for treatment is surgical resection. Imatinib, a tyrosine kinase inhibitor, is the primary therapy for unresectable, recurrent or metastatic disease. ConclusionsGastrointestinal stromal tumours are rare tumours of the gastrointestinal tract and they vary in presentation. When surgical resection is not achievable, imatinib is the treatment of choice.

show abstract

Section: Clinical Presentation and Diagnosismentioning

confidence: 99%

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Iorio

Sawaya

Friedenberg

2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A common problem for the diagnosis of GISTs is that conventional endoscopic biopsies using forceps are often unsuccessful in sampling submucosal mass, because they are too superficial and only obtain biopsy samples of the mucosal tissue. EUSguided aspiration or core biopsy for submucosal tumors had a success rate of 60%-70% in the earlier studies, but this rate is now gradually reaching 80%-90%, which is significantly higher than that of a simple endoscopic biopsy [10][11][12] . The usefulness of biopsy in diagnosis can be enhanced by immunohistochemical staining on aspirates or tissues for tumor-specific markers such as CD117 and CD34, which are crucial for a diagnosis of GISTs [13] .…”

Section: Discussionmentioning

confidence: 91%

Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor

Hou¹,

Zhou²,

Lu³

et al. 2009

WJG

View full text Add to dashboard Cite

Surgical treatments including radical resection and local excision remain the main treatment for primary rectal gastrointestinal stromal tumors (GISTs). However, since patients with high-grade rectal GISTs have a higher risk of tumor recurrence and a shorter life expectancy, neoadjuvant treatment is necessary. In this case report, the efficacy of imatinib mesylate (IM) as a neoadjuvant therapy was assessed in an old man with malignant rectal GIST. The patient received IM preoperative treatment for a short period of one and a half months; at the end of the IM treatment, computed tomography scanning showed a markedly reduced tumor size and cystic changes of the tissue. At that time, a function sphincter-sparing surgery was performed. The histological examination of the resected specimen detected no tumor cells, but residual blood vessels and scattered inflammatory lymphocytes. After surgery, the patient has been followed up without additional IM treatment and remained disease-free for 57 mo. This case indicates that IM neoadjuvant therapy can dramatically improve the prognosis of rectal malignant GIST.

show abstract

“…A few case reports and studies have shown EUS-FNA as a feasible technique for obtaining tissue samples from thickened folds or other lesions within the GI tract wall, especially when endoscopic biopsies are negative. One retrospective study of EUS-FNA in evaluating intramural and extramural GI tract lesions showed the sensitivity, specificity, and diagnostic accuracy of EUS-FNA in diagnosing GI tract neoplastic lesions were 89%, 88%, and 89%, respectively [51]. The staging of PGL is different than for gastric adenocarcinoma and utilizes either the modified Ann Arbor staging system or the modified TNM staging system named the Paris classification [52,53].…”

Section: Infiltrating Gastric Malignanciesmentioning

confidence: 99%

EUS Staging of Luminal Cancers in the Upper GI Tract

Bucobo¹,

Buscaglia²

2011

New Techniques in Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy

Cited by 219 publications

References 61 publications

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor

EUS Staging of Luminal Cancers in the Upper GI Tract

Contact Info

Product

Resources

About